Annals of African Medicine
Home About AAM Editorial board Ahead of print Current Issue Archives Instructions Subscribe Contact us Search Login 
CASE REPORT
Year : 2020  |  Volume : 19  |  Issue : 3  |  Page : 207-210

Refractory lupus panniculitis treated successfully with rituximab: Two cases


1 Department of Internal Medicine, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India
2 Department of Rheumatology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India

Correspondence Address:
Dr. Prasanta Padhan
Department of Rheumatology, Kalinga Institute of Medical Sciences, Bhubaneswar - 751 024, Odisha
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/aam.aam_42_19

Rights and Permissions

Lupus panniculitis is usually difficult to treat, and the patient is often put on multiple immunosuppressives with variable clinical response and relapses, notwithstanding the long-term side effects. We describe two cases of refractory lupus panniculitis which have been treated successfully with rituximab which is a chimeric anti-CD20 antibody. It reduces the number of circulating mature B-cells, thereby reducing the autoantibodies and the mediators of inflammation. Rituximab is a good alternative to patients who are not responsive to conventional treatment options for lupus panniculitis. There have been few side effects reported by the patients, but the clinical response and psychological well-being clearly outweigh them.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed233    
    Printed21    
    Emailed0    
    PDF Downloaded2    
    Comments [Add]    

Recommend this journal